ESG26 Aug 2026, 08:20 pm
Cohance Lifesciences Files FY26 Business Responsibility and Sustainability Report
AI Summary
Cohance Lifesciences Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as required by SEBI regulations. The report details the company's performance across environmental, social, and governance (ESG) parameters. Key disclosures include its business activities, market reach, employee details, and operational locations. The company operates primarily in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products, with a significant portion of its turnover derived from exports. The BRSR report has undergone reasonable assurance assessment by Sustainability Actions Private Limited.
Key Highlights
- Cohance Lifesciences filed its FY25-26 BRSR report.
- Report covers ESG parameters and business operations.
- Manufacturing of pharmaceuticals is the core business activity.
- Exports contribute significantly to total turnover (84%).
- BRSR report received reasonable assurance.
Price Impact
More from COHANCE